Abstract:Introduction: Acquired von Willebrand syndrome (aVWS) is common in patients with severe aortic stenosis (sAS), which is characterized by the loss of high-molecular-weight multimers (HMWM) of the von Willebrand factor (VWF). VWF abnormalities are improved after surgical aortic valve replacement (SAVR). While conventional multimer analysis is technically challenging, lengthy and non-standardized, recently a new semi-automated multimer assay, the Hydragel 5 VWF multimers (H5VWM) has become available. Therefore, the aim of our study was to analyze VWF abnormalities by H5VWM in patients undergoing SAVR in terms of echocardiography parameter and perioperative bleeding. Methods: We prospectively included 52 patients (age: 67.9±7.2 years; 53.8% male) undergoing SAVR. Patients were divided in two groups (A: abnormal VWF, n=24; B: normal VWF, n=28). Blood samples and echocardiographic data were collected at three time points (TP): day before SAVR (TP1), 7 days (TP2), and 3 months (TP3) after SAVR. Blood loss from chest drainage and the use of blood and haemostatic products were evaluated peri- and postoperatively. Results: Baseline characteristics were similar in both groups. Loss of HMWM was present in 38.5%. After SAVR the level of HMWM had increased significantly compared to baseline in group A. At TP3, we observed no loss of HMWM at all. Bleeding occurred in 15% (A: 17% vs. B: 14%; p>0.999) with need of re-thoracotomy in about 10% (A: 8% vs. B: 11%; p>0.999). There was no significant difference in postoperative bleeding in the first 24hrs (A: 491 ml vs. B: 701ml; p=0.255). Also, peri- and postoperative need of blood transfusion and haemostatic agents were similar between both groups. HMWM was inversely correlated with the peak aortic gradient (R=-0.557; p<0.001) and positively correlated with the aortic valve area (R=0.292; p=0.04). Conclusion: Loss of HMWM was not associated with increased postoperative bleeding in patients with sAS. Echocardiographic parameters could predict the loss of HMWM. The complete restoration of altered VWF at three months postoperatively, demonstrated by H5VWM, seems to be indicative for successful SVAR. Therefore, H5VWM, as a rapid and sensitive assay, could be included as diagnostic tool of suspected aVWS in AS patients.

Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology

Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures

Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone

Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias

Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease

Progress in von Willebrand Disease Treatment: Evolution towards Newer Therapies

Misleading antigenic von Willebrand factor levels in acquired von Willebrand syndrome secondary to monoclonal gammopathy of undetermined significance

Acquired von Willebrand syndrome during extracorporeal membrane oxygenation support: a comprehensive review of current evidence: communication from the ISTH SSC on perioperative and critical care thrombosis and hemostasis

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

Improved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease

A case of hyperviscosity syndrome associated with Waldenström macroglobulinemia treated with membrane plasma exchange without predilution

Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenström Macroglobulinemia with MYD88 and CXCR4 Mutations

Abstract 11397: Impact of Von Willebrand Factor Multimer Abnormalities on Blood Loss After Aortic Valve Replacement Using the Semi-Automated Hydragel 5 Multimer Assay

How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease

Investigation of von Willebrand factor multimer abnormalities before and after aortic valve replacement using the Hydragel-5 assay

von Willebrand disease: what does the future hold?

Bleeding Mystery Unveiled: A Case of Acquired Hemophilia A in the Shadow of Multiple Myeloma